These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 18196360)

  • 41. Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.
    Zampa G; Moscato M; Brannigan BW; Morabito A; Bell DW; Normanno N
    Lung Cancer; 2008 Jun; 60(3):452-4. PubMed ID: 18079016
    [TBL] [Abstract][Full Text] [Related]  

  • 42. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
    Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
    J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
    Katayama T; Shimizu J; Suda K; Onozato R; Fukui T; Ito S; Hatooka S; Sueda T; Hida T; Yatabe Y; Mitsudomi T
    J Thorac Oncol; 2009 Nov; 4(11):1415-9. PubMed ID: 19692934
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients.
    Wu CH; Fan WC; Chen YM; Chou KT; Shih JF; Tsai CM; Lee YC; Perng RP
    J Thorac Oncol; 2010 Mar; 5(3):376-9. PubMed ID: 20104191
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors.
    Ansén S; Bangard C; Querings S; Gabler F; Scheffler M; Seidel D; Saal B; Zander T; Nogová L; Töpelt K; Markert E; Stoelben E; Ernestus K; Thomas RK; Wolf J
    J Thorac Oncol; 2010 Mar; 5(3):407-9. PubMed ID: 20186030
    [No Abstract]   [Full Text] [Related]  

  • 46. Remarkable bone formation following gefitinib for extensive lytic bone metastasis: a report of two cases.
    Bashir ES; Kwan AK; Chan CY; Mun Keong K
    J Orthop Surg (Hong Kong); 2016 Dec; 24(3):421-423. PubMed ID: 28031519
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of lung cancer.
    Seruga B; Amir E; Tannock I
    N Engl J Med; 2009 Dec; 361(25):2485; author reply 2486-7. PubMed ID: 20050212
    [No Abstract]   [Full Text] [Related]  

  • 48. Prognostic Factors and Comparison of Conservative Treatment, Percutaneous Vertebroplasty, and Open Surgery in the Treatment of Spinal Metastases from Lung Cancer.
    Yang SZ; Tang Y; Zhang Y; Chen WG; Sun J; Chu TW
    World Neurosurg; 2017 Dec; 108():163-175. PubMed ID: 28867314
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A prediction model of survival for patients with bone metastasis from uterine cervical cancer.
    Matsumiya H; Todo Y; Okamoto K; Takeshita S; Yamazaki H; Yamashiro K; Kato H
    J Gynecol Oncol; 2016 Nov; 27(6):e55. PubMed ID: 27550401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis.
    Hashisako M; Wakamatsu K; Ikegame S; Kumazoe H; Nagata N; Kajiki A
    Tohoku J Exp Med; 2012 Oct; 228(2):163-8. PubMed ID: 23036980
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Two lung adenocarcinoma patients with multiple brain metastasis treated with Gefitinib and surviving more than 2 years].
    Matsuyama W; Yamamoto M; Machida K; Mitsuyama H; Watanabe M; Higashimoto I; Osame M; Arimura K
    Nihon Kokyuki Gakkai Zasshi; 2006 Sep; 44(9):653-8. PubMed ID: 17037411
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical analysis of patients with skeletal metastasis of lung cancer.
    Cho YJ; Cho YM; Kim SH; Shin KH; Jung ST; Kim HS
    BMC Cancer; 2019 Apr; 19(1):303. PubMed ID: 30943924
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Analysis of Survival Predictors in Patients with Lung Cancer and Brain Metastases].
    Cui S; Bai H; Dong L; Zhao Y; Gu A; Zhang W; Lou Y; Jiang L
    Zhongguo Fei Ai Za Zhi; 2015 Jul; 18(7):436-42. PubMed ID: 26182869
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis].
    Okano Y; Nishio M
    Clin Calcium; 2008 Apr; 18(4):527-33. PubMed ID: 18379035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tyrosine kinase inhibitor sunitinib therapy is effective in the treatment of bone metastasis from cancer of unknown primary: Identification of clinical and immunohistochemical biomarkers predicting survival.
    Ma Y; Zhou W; He S; Xu W; Xiao J
    Int J Cancer; 2016 Sep; 139(6):1423-30. PubMed ID: 27164264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers.
    Chambard L; Girard N; Ollier E; Rousseau JC; Duboeuf F; Carlier MC; Brevet M; Szulc P; Pialat JB; Wegrzyn J; Clezardin P; Confavreux CB
    Bone; 2018 Mar; 108():202-209. PubMed ID: 29337225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic factors in adult patients with solid cancers and bone marrow metastases.
    Hung YS; Chou WC; Chen TD; Chen TC; Wang PN; Chang H; Hsu HC; Shen WC; Cheng WH; Chen JS
    Asian Pac J Cancer Prev; 2014; 15(1):61-7. PubMed ID: 24528082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical Characteristics and Prognostic Factors in Bone Metastases from Lung Cancer.
    Zhang L; Gong Z
    Med Sci Monit; 2017 Aug; 23():4087-4094. PubMed ID: 28835603
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Invited Commentary.
    Watzka SB
    Ann Thorac Surg; 2015 Aug; 100(2):421. PubMed ID: 26234831
    [No Abstract]   [Full Text] [Related]  

  • 60. Prognostic factors for patients with solitary bone metastasis.
    Hoshi M; Takada J; Ieguchi M; Takahashi S; Nakamura H
    Int J Clin Oncol; 2013 Feb; 18(1):164-9. PubMed ID: 22173837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.